CNR ExploRA

Articolo in rivista, 2022, ENG, 10.3390/nano12142372

Graphene Oxide Nanoplatforms to Enhance Cisplatin-Based Drug Delivery in Anticancer Therapy

Elena Giusto, Ludmila ?árská , Darren Fergal Beirne, Arianna Rossi, Giada Bassi, Andrea Ruffini, Monica Montesi, Diego Montagner, Vaclav Ranc, Silvia Panseri

1 Institute of Science and Technology for Ceramics-National Research Council (CNR), 48018 Faenza (RA), Italy; elena.giusto@aol.com (E.G.); arianna.rossi@istec.cnr.it (A.R.); giada.bassi@istec.cnr.it (G.B.); andrea.ruffini@istec.cnr.it (A.R.); monica.montesi@istec.cnr.it (M.M.) 2 Regional Centre of Advanced Technologies and Materials, Czech Advanced Technology and Research Institute, Palacký University Olomouc, 78371 Olomouc, Czech Republic; ludmila.zarska@centrum.cz 3 Department of Chemistry, Maynooth University, Maynooth, Ireland; darren.beirne.2017@mumail.com 4 Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Studies of Messina, 98100 Messina (ME), Italy 5 Department of Neuroscience, Imaging and Clinical Sciences, University of Studies G. d'Annunzio Chieti-Pescara, 66100 Chieti (CH), Italy 6 Institute of Molecular and Translation Medicine, Faculty of

Chemotherapeutics such as platinum-based drugs are commonly used to treat several cancer types, but unfortunately, their use is limited by several side effects, such as high degradation of the drug before entering the cells, off-target organ toxicity and development of drug resistance. An interesting strategy to overcome such limitations is the development of nanocarriers that could enhance cellular accumulation in target cells in addition to decreasing associated drug toxicity in normal cells. Here, we aim to prepare and characterize a graphene-oxide-based 2D nanoplatform functionalised using highly branched, eight-arm polyethylene-glycol, which, owing to its high number of available functional groups, offers considerable loading capacity over its linear modalities and represents a highly potent nanodelivery platform as a versatile system in cancer therapy. The obtained results show that the GO@PEG carrier allows for the use of lower amounts of Pt drug compared to a Pt-free complex while achieving similar effects. The nanoplatform accomplishes very good cellular proliferation inhibition in osteosarcoma, which is strictly related to increased cellular uptake. This enhanced cellular internalization is also observed in glioblastoma, although it is less pronounced due to differences in metabolism compared to osteosarcoma. The proposed GO@PEG nanoplatform is also promising for the inhibition of migration, especially in highly invasive breast carcinoma (i.e., MDA-MB-231 cell line), neutralizing the metastatic process. The GO@PEG nanoplatform thus represents an interesting tool in cancer treatment that can be specifically tailored to target different cancers.

Nanomaterials (Basel) 12